Article
Clinical significance of tumour mutation burden in immunotherapy across multiple cancer types: an individual meta-analysis.
Japanese journal of clinical oncology - 5 Sept 2020
Yang Zhenyu, Wei Shiyou, Deng Yulan, Wang Zihuai, Liu Lunxu
Abstract excerpt
BACKGROUND: Biomarkers for stratifying patients that could benefit from immune checkpoint inhibitors are necessary. Tumour mutation burden has recently become a promising biomarker in cancer, but the associations between tumour mutation burden and outcomes of immune checkpoint inhibitors treatment were not well-documented in present studies. METHODS: We searched PubMed, Web of Science and EMBASE databases up to 1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.